11/17
09:46 am
elab
Elevai Labs Third Quarter 2024 Earnings: US$0.068 loss per share (vs US$0.078 loss in 3Q 2023) [Yahoo! Finance]
Medium
Report
Elevai Labs Third Quarter 2024 Earnings: US$0.068 loss per share (vs US$0.078 loss in 3Q 2023) [Yahoo! Finance]
11/14
02:35 pm
elab
CORRECTION - Elevai Labs Inc.
Low
Report
CORRECTION - Elevai Labs Inc.
11/14
09:17 am
elab
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update [Yahoo! Finance]
High
Report
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update [Yahoo! Finance]
11/14
09:08 am
elab
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
High
Report
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
11/4
05:48 pm
elab
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange [Yahoo! Finance]
Medium
Report
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange [Yahoo! Finance]
11/4
05:45 pm
elab
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange
Low
Report
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange
10/22
09:59 am
elab
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity [Yahoo! Fina
Low
Report
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity [Yahoo! Fina
10/22
09:54 am
elab
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity
Medium
Report
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity
10/21
07:30 am
elab
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity
High
Report
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity
10/4
05:16 pm
elab
Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock [Yahoo! Finance]
Medium
Report
Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock [Yahoo! Finance]
10/4
05:08 pm
elab
Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock
Medium
Report
Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock
10/3
03:45 pm
elab
REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
Neutral
Report
REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
10/3
10:01 am
elab
Elevai Bioscience up on portfolio expansion with new filings for muscle loss treatment in obese patients [Seeking Alpha]
Low
Report
Elevai Bioscience up on portfolio expansion with new filings for muscle loss treatment in obese patients [Seeking Alpha]
10/3
07:30 am
elab
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
High
Report
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
10/2
08:30 am
elab
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device
Low
Report
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device
9/24
05:00 pm
elab
Univest Securities, LLC Announces Closing of $8.0 Million Registered Follow-on Offering for its Client Elevai Labs Inc. (NASDAQ: ELAB)
Low
Report
Univest Securities, LLC Announces Closing of $8.0 Million Registered Follow-on Offering for its Client Elevai Labs Inc. (NASDAQ: ELAB)
9/23
08:54 am
elab
Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering [Yahoo! Finance]
Medium
Report
Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering [Yahoo! Finance]
9/23
08:45 am
elab
Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering
High
Report
Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering
9/10
07:42 am
elab
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications [Yahoo! Finance]
Medium
Report
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications [Yahoo! Finance]
9/10
07:30 am
elab
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications
Low
Report
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications
9/3
07:30 am
elab
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology
High
Report
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology
8/28
07:30 am
elab
Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBio? Y100™ Mitochondrial Innovation and Elevai Exosomes™
High
Report
Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBio? Y100™ Mitochondrial Innovation and Elevai Exosomes™
8/26
07:30 am
elab
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum
High
Report
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum